MMP inhibitors in cardiac diseases: An update

Recent Patents on Cardiovascular Drug Discovery

Volumn 2, Issue 3, 2007, Pages 186-194

  Dormán, György ^a   Kocsis Szommer, Katalin ^a   Spadoni, Cesare ^a   Ferdinandy, Péter ^b,c  

^a AMRI   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c PHARMAHUNGARY GROUP   (Hungary)

Author keywords

Efficacy; Heart failure; Infarction; Inhibitors; Matrix metalloproteinase; MMP; Remodelling; Safety; Selectivity

Indexed keywords

BIPHENYL HYDROXAMATE; CARDIOVASCULAR AGENT; CONTRAST MEDIUM; COPPER; DOXYCYCLINE HYCLATE; FERROMAGNETIC MATERIAL; GALLIUM; HYDROXAMIC ACID DERIVATIVE; INDIUM 111; IODINE 123; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 1 INHIBITOR; MATRIX METALLOPROTEINASE 10 INHIBITOR; MATRIX METALLOPROTEINASE 12 INHIBITOR; MATRIX METALLOPROTEINASE 13 INHIBITOR; MATRIX METALLOPROTEINASE 2 INHIBITOR; MATRIX METALLOPROTEINASE 3 INHIBITOR; MATRIX METALLOPROTEINASE 7 INHIBITOR; MATRIX METALLOPROTEINASE 8 INHIBITOR; MATRIX METALLOPROTEINASE 9 INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; METALLOPROTEINASE INHIBITOR; PHOSPHOLIPID; POLYMER; PROPIONIC ACID DERIVATIVE; RADIOISOTOPE; SUCCINIC ACID DERIVATIVE; TECHNETIUM 99M; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINC;

ARTHRITIS; ARTICLE; BINDING SITE; CARDIOVASCULAR DISEASE; CHEMICAL MODIFICATION; CLINICAL FEATURE; DIAGNOSTIC VALUE; DISEASE MARKER; DRUG DESIGN; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME ASSAY; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME STRUCTURE; ENZYME SUBSTRATE; GAMMA RADIATION; GENOMICS; HEART DISEASE; HUMAN; MUSCULOSKELETAL DISEASE; NEOPLASM; PATENT; PERIODONTAL DISEASE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN TARGETING; RADIODIAGNOSIS;

CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MATRIX METALLOPROTEINASES; MUSCULOSKELETAL DISEASES; STRUCTURE-ACTIVITY RELATIONSHIP; SYNDROME;

EID: 36749017556     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489007782418964     Document Type: Article

References (38)

1. Fingleton B. Matrix metalloproteinases as valid clinical targets. Curr Pharm Des 2007; 13(3): 333-346.
2. Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol 2007; 47: 211-242.
3. Ferdirnandy P. Peroxynitrite: just an oxidative/nitrosative stressor or a physiological regulator as well? Br J Pharmacol 2006; 148: 1-3.
4. Csonka C, Csont T, Onody A, Ferdinandy P. Preconditioning decreases ischemia/reperfusion-induced peroxynitrite formation. Biochem Biophys Res Commun 2001; 285: 1217-1219.
5. Lalu M, Csonka C, Giricz Z, Csont T, Schulz R, Ferdinandy P. Preconditioning decreases ischemia/repurfusion-induced release and activation of matrix metalloproteinase-2. Biochem Biophys Res Commun 2002; 296: 937-941.
6. Giricz Z, Lalu MM, Csonka C, Bencsik P, Schulz R, Ferdinandy P. Hyperlipidemia attenuates the infarct size-limiting effect of ischemic preconditioning: role of matrix metalloproteinase-2 inhibition. J Pharmacol Exp Ther 2007; 316: 154-161.
7. Matter H, Schudok M. Recent advances in the design of matrix metalloprotease inhibitors. Curr Opin Drug Discov Devel 2004; 4: 513-35.
8. Skiles JW. The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors. Curr Med Chem 2004; 11: 2911-2977.
9. Devel L, Rogakos V, David A, et al. Development of selective inhibitors and substrate of matrix metalloproteinase-12. J Biol Chem 2006; 281(16):11152-11160.
10. Viappiani S, Sariahmetoglu M, Schulz R. The role of matrix metallo-proteinase inhibitors in ischemia-reperfusion injury in liver. Curr Pharm Des 2006; 12(23):2923-2934.
11. Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol 2007; 47: 211-242.
12. Peterson JT. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev 2004; 9(1): 63-79.
13. Wada CK. The evolution of the matrix metalloproteinase inhibitor drug discovery program at Abbott laboratories. Curr Top Med Chem 2004; 4(12): 1255-1267.
14. Pirard B, Matter H. Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis. J Med Chem 2006; 49(1): 51-69.
15. Lukacova V, Zhang Y, Mackov M, et al. Similarity of binding sites of human matrix metalloproteinases. J Biol Chem 2004; 279(14): 14194-14200.
16. Skiles JW, Gonnella NC, Jeng AY. The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. Curr Med Chem 2001; 8(4): 425-74.
17. Skiles JW, Gonnella NC, Jeng AY. Tle design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors. Curr Med Chem 2004; 22: 2911-2977.
18. Papp, A, Szommer T, Spadoni C, et al. Expert Op Drug Disc (in press).
19. Floersheim P, Pombo-Villar E, Shapiro G. Chimia 1992; 46: 323-334.
20. Fujita T. Similarities in bioanalogous structural transformation patterns among various bioactive compound series. Biosci Biotechnol Biochem 1996; 60(4): 557-66.
21. Chen X, Wang W. The use of bioisosteric groups in lead optimization. Ann Rep Med Chem 2003; 38, Elsevier, Amsterdam.
22. Lima LM, Barreiro EJ. Bioisosterism: a useful strategy for molecular modification and drug design. Curr Med Chem 2005; 12(1):2349.
23. Olsen PH. The use of bioisosteric groups in lead optimization. Curr Opin Drug Discov Devel 2001; 4(4): 471-478.
24. Metalloprotease inhibitors. Exp Op Therap Patents 1998; 8: 1191-1194.
25. Reverse hydroxamate derivatives as metalloprotease inhibitors. Exp Opin Therap Patents 1999; 9: 1575-1578.
26. Holmes, I., Watson, S.P.: WO05016868A2 (2005).
27. Holmes, I., Watson, S.P.: WO04113279 (2004).
28. Gaines, S., Holmes, I., Watson, S.P.: WO04110974A1 (2004).
29. Gaines, S., Holmes, I., Martin, S.L., Watson, S.P.: WO05026120A1 ( 2005).
30. Mantegani, S., Abrate, F., Bissolino, P.: US20046765003 (2004).
31. Burns, D.M., Yao, W., He, C.: US20050250789A1 (2005).
32. Kim DY, Lee JY, Kim JS, et al. Synthesis and biological evaluation of 3-(4-substituted-phenyo-N-hydroxy-2-propenamides, a new class of histone deacetylase Inhibitors. J Med Chem 2003; 46: 5745-5751.
33. Carpino LA, Xia J, El -Faham A. 3-Hydroxy-4-oxo-3,4-dihydro-5-azabenzo-1,2,3-triazene. J Org Chem 2004; 69: 54.
34. Li, Y.L., Zhuo, J.: US20050113344A1 (2005).
35. Harris, T.D., Yalamanchili, P.: US20050106100A1 (2005).
36. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-671.
37. Decicco, C., Nelson, D.J., Barrett, J.A., Carpenter Jr. A.P.: US20066989139 (2006).
38. Decicco, C., Nelson, D.J., Barrett, J.A., Carpenter Jr. A.P.: US20050025702A1 (2005).